Diabetic Foot Ulcer Program

 

For more information please e-mail us at: info@regenestem.com

Diabetic Foot Ulcer – Heberprot-P

Heberprot-P is a drug developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Cuba for the treatment of severe diabetic foot ulcer which has epidermal growth factor (EGF) as it’s main ingredient and is parenteral administered (intra-lesional injections directly in the wound). About 160,000 diabetic foot ulcer patient have been treated with Heberprot-P with success reducing the the risk of amputation by %75.

Diabetic patients have a decreased amount of growth factor concentrations, mainly epidermal growth factor receptor (EGF). EGF is an important growth factor that promote cell growth and cell proliferation by binding to the epidermal growth factor receptors (EGFR). A reduced amount of EGF impairs wound healing to such extremes as to may require amputation. Heberprot-P encourages healing in a progressive and sustained manner.

Heberprot-P is given for treatment for patient suffering chronic non-healing wounds with poor prognosis and those not responding to extensive conventional methods of treatment.